Romaco Group Sells FrymaKorum?a to ProXES
The Romaco Group is selling its stake in FrymaKoruma AG (Rheinfelden, Switzerland) and FrymaKoruma GmbH (Neuenburg) to a new umbrella corporation within the Deutsche Beteiligungs AG (DBAG Frankfurt).
“During more than 10 years in affiliation with the Romaco Group, FrymaKoruma developed very well. We are pleased to offer a further growth spurt to the company in a group that specialises in process technology. Through this transaction, Romaco will focus even more on the development of its competences, especially in the pharmaceuticals market,” says Paulo Alexandre, CEO of the Romaco Group.
The companies Stephan Machinery (Hameln) and FrymaKoruma will co-operate under the new umbrella corporation ProXES. Both companies have strong brands in the area of food, pharmaceutical and health care technology and they also see an excellent complement to their previous applications and their market presence in their common future. A clear focus on process technology will ensure a stronger market position under the common umbrella corporation. Therefore, the DBAG portfolio company ProXES is acquiring the entire stake in FrymaKoruma (AG and GmbH) from the Romaco Group.
“Within the Romaco Group, we were already able to make use of significant incentives for the development of FrymaKoruma”, says Thomas Merle, director of FrymaKoruma, a little wistful about leaving the group. “We are very pleased that we can now realise previously unknown possibilities within our core business with the help of ProXES and its clear focus on process technology.”
Olaf Pehmöller, CEO of Stephan Machinery, is also happy about their new partner. “FrymaKoruma and Stephan Machinery complement each other to the benefit of both companies. For our customers, we are developing a process technology group consistent with an enterprise size which can offer more attractive proposals in better quality”, says Pehmöller, who will also act as CEO for the ProXES Group.
ProXES stands for ‘Processing and eXpert Engineering Services’, whereby the new name is at the same time a promise to our customers and thus a responsibility for the new partners. The principal shareholder is also satisfied with this focus: “With FrymaKoruma and Stephan Machinery, we have two companies which are active on the market with strong brands and an excellent reputation. The combining of the respective excellences is the logical consequence of our growth strategy which we will now implement in a focussed way”, says Dr Rolf Scheffels, member of the board of the Deutsche Beteiligungs AG.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.